Cooper's 357% "Beat" Is a Tax Mirage. The Miss Is Real — and So Is the Cash Flow.

CooperCompanies just put up a headline number that looks like a blowout: GAAP earnings per share of $2.24, up about 357% from a year ago. And it just had one of its worst days in years — the stock fell 6% in the regular session and kept sliding, roughly another 16% after hours. Both things came out of the same quarterly report, and the gap between them is the entire story.

When a company reports 357% earnings growth and the market still sells it hard, the growth is almost always an artifact rather than an operating result. That is exactly what happened here. The $2.24 was inflated by a one-time, $307 million tax benefit from a U.K. tax authority completing its review of a 2021 intellectual-property transfer. Strip it out and the underlying business barely grew: non-GAAP net income rose just 1% from a year ago.

The market was not ignoring the earnings — it was reading the revenue line. Fiscal third-quarter sales came in at $1.066 billion, up 1%, a miss against the roughly $1.1 billion analysts expected. That is a sharp step-down from the 8% growth Cooper printed the prior quarter, and it is the reason the stock is being repriced.

The engine stalled — and why

The business is two halves. CooperVision, the contact-lens division that delivers roughly two-thirds of revenue, is the growth engine, and it went flat: 0% organic growth for the quarter, dragged down by a U.S. channel inventory reduction. EMEA still grew, but the Americas and Asia Pacific both fell.

What matters for a beaten-down-growth view is the why, because not all stalls are created equal. Management describes this as a deliberate, finite inventory correction: optical chains had stocked up ahead of price increases, private-label wins, and IT upgrades, and are now working that stock down. Underlying U.S. consumption, it says, is still growing in the mid-single digits. The destocking is roughly half done and mostly wraps up in the fourth quarter — which is why CooperVision is guiding to negative-2% to flat organic growth in Q4. That is a negative number, and investors sold it hard.

Here is the honest distinction the selloff forces you to make. This is not a case where the operating path stayed intact and only sentiment turned ugly — the near-term path genuinely worsened, and guidance for the core business is now negative to flat. So the 17% drop is not pure fear. But the mechanism is specific and finite, not demand destruction. Consumers are still buying lenses; the channel is just holding less inventory.

The cash-flow bridge

This is where the numbers stop being a puzzle and turn into the thing I trust. Cooper produced a record $273 million of free cash flow in the quarter, up 66%, and $528 million for the first nine months, up 86%. Management reaffirmed its goal of $2.2 billion of cumulative free cash flow across fiscal 2026 through 2028.

That is the tension in the whole pitch: a business that grew 1% this quarter while throwing off more cash than it ever has. A broken thesis normally shows up as vanishing cash flow. Here the opposite happened. The low price is real, but so is the cash conversion.

Be clear-eyed about the offsets, because this is where the bear case lives. Buybacks ran ahead of free cash flow in the quarter, partly financed by borrowing, and the company now expects about $170 million of Q4 free cash flow that excludes some $272 million of litigation payments. A fertility-related litigation accrual ballooned to roughly $316 million on the balance sheet. Margins took a 60-basis-point hit from manufacturing costs and foreign exchange. And the effective tax rate steps up about two points next fiscal year.

Which brings the thesis to one break condition: CooperVision's organic growth has to turn positive once the destocking ends and re-accelerate toward the contact-lens market's 4% to 6% pace, with that free cash flow holding up. Management says the inventory overhang clears by fiscal 2027 — and it has declined to give a specific fiscal 2027 outlook until December. That December guidance is the date that actually matters. If lens growth recovers off the inventory work, the now-lower price re-rates. If it does not, the stock stays cheap because it should.

So the fall is partly deserved, and the pain is not only on the tape. But the free cash flow is real, and the drag is discrete rather than structural. The mistake would be to buy the stock off a tax-inflated earnings print; the smarter move is to let the December outlook answer whether the inventory correction actually translated into recovered lens growth — and to keep the tax gain out of the decision entirely.